Celldex Therapeutics reported $598.36M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celldex Therapeutics USD 598.36M 57.04M Sep/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025